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Key Points
1. Hepatitis B virus variants with antiviral drug–resis-
tant mutations and/or hepatitis B immune globu-
lin–resistant mutations are the main cause of hepa-
titis B virus reinfections post–liver transplant.
2. Early diagnosis of antiviral drug resistance and
prompt initiation of rescue therapy are important in
preventing hepatitis flares and hepatic decompensa-
tion.
3. Virologic breakthrough is the first indication of an-
tiviral drug resistance.
4. Genotypic resistance testing should be performed
when possible to avoid unnecessary modification of
treatment in patients who do not have confirmed
antiviral drug resistance and to permit appropriate
selection of rescue therapy in those who have con-
firmed antiviral drug resistance.
5. Choice of rescue therapy requires knowledge of the
past history of hepatitis B virus treatments and vi-
rologic response to those treatments, patterns of
mutations detected at the time of virologic break-
through, and in vitro cross-resistance data.
6. Occurrence of antiviral drug resistance can be re-
duced by the use of the most potent nucleos(t)ide
analogue(s) with the highest genetic barrier to resis-
tance, emphasis of medication compliance, and
close monitoring of virologic response. Liver Transpl
14:S8-S14, 2008. © 2008 AASLD.
The availability of orally administered nucleos(t)ide
analogues that are safe and effective in suppressing
hepatitis B virus (HBV) replication in pre– and post–
liver transplant patients has revolutionized the man-
agement of these patients. However, these therapies do
not eradicate HBV. Therefore, most patients require
long-term treatment to maintain virus suppression.
Life-long treatment is generally recommended for liver
transplant patients to prevent hepatitis flares associ-
ated with virologic relapse because these flares may
lead to rapid decompensation and death in patients
who have limited hepatic reserve or are immunosup-
pressed, but the risk of antiviral drug resistance in-
creases with the duration of treatment. Thus, while the
use of nucleos(t)ide analogues pre-transplant and com-
bination of nucleos(t)ide analogues and hepatitis B im-
mune globulin (HBIG) post-transplant have been
shown to reduce the rate of HBV reinfection post-trans-
plant to less than 10%, almost all cases of HBV reinfec-
tion are due to HBV variants with antiviral drug–resis-
tant mutations and/or HBIG-resistant mutations.1-3
This review discusses the nomenclature, diagnosis,
treatment, and prevention of HBV antiviral drug resis-
tance.
NOMENCLATURE
Antiviral drug resistance may be reported as pheno-
typic resistance, genotypic resistance, viral resistance,
or clinical resistance. Table 1 summarizes the defini-
tions of the most common terms used to describe anti-
viral drug resistance.4 Phenotypic resistance is defined
as decreased susceptibility (ie, increased concentra-
tions of the drug are needed to achieve 50% or 90%
inhibition) of an HBV polymerase to an antiviral drug in
in vitro assays. Genotypic resistance is defined as the
detection during antiviral therapy of viral populations
Abbreviations: HBIG, hepatitis B immune globulin; HBV, hepatitis B virus; MALDI-TOF, matrix-assisted laser desorption/ionization
time-of-flight; RFLP, restriction fragment length polymorphism.
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bearing amino acid substitutions in the reverse tran-
scriptase region of the HBV polymerase gene that have
been shown to confer resistance to antiviral drugs in
phenotypic assays. Viral resistance or virologic break-
through is defined as an increase in serum HBV DNA by
at least 1 log10 (10-fold) above nadir or the reappear-
ance of serum HBV DNA in the patient with previously
undetectable HBV DNA on 2 occasions at least 1
month apart while the patient is on treatment and after
initial response is achieved in the medication-compli-
ant patient. The term clinical resistance is often used
synonymously with biochemical breakthrough and is
defined as an elevation in serum alanine aminotrans-
ferase while the patient is on treatment and after nor-
malization is achieved in the medication-compliant pa-
tient. Ascertainment of medication compliance is
problematic because assays for monitoring nucleo-
s(t)ide drug concentrations are not readily available and
self-reporting by patients may not be reliable. As many
as 30% to 50% of virologic breakthroughs observed in
clinical trials are attributed to noncompliance with
medications5-8; this figure is likely higher in clinical
practice.
DIAGNOSIS
Genotypic resistance may precede viral resistance (vi-
rologic breakthrough) by many months, and viral resis-
tance may precede clinical resistance (biochemical
breakthrough) by months to years. Because of the po-
tential devastating effect of biochemical breakthrough
in liver transplant patients, early diagnosis of antiviral
drug resistance and prompt intervention are critical.
Thus, confirmation of virologic breakthrough on repeat
testing is not necessary if there is a marked increase in
serum HBV DNA or if there is accompanying biochem-
ical breakthrough.
Detection of virologic breakthrough requires knowl-
edge of the pretreatment serum HBV DNA level, docu-
mentation of initial response, determination of nadir or
lowest HBV DNA level achieved, and detection of a 1
log10 increase (or reappearance) in the HBV DNA level.
Therefore, establishment of the baseline serum HBV
DNA level and regular monitoring, preferably at
3-month intervals with the same HBV DNA assay at
each measure, are necessary for the diagnosis of viral
resistance. Without documentation of initial response,
it is not possible to determine if a patient who has a high
serum HBV DNA level after a long duration (6 months)
of nucleos(t)ide analogue therapy has never achieved
adequate viral suppression or instead has virologic
breakthrough. This is particularly problematic for pa-
tients receiving adefovir, which has weak antiviral ac-
tivity at the approved dose.
Because not all breakthroughs are due to drug resis-
tance, confirmation with genotypic resistance testing
should be performed whenever possible. This will avoid
unnecessary modification of treatment in patients who do
not have confirmed antiviral drug resistance and permit
appropriate selection of rescue therapy in those who have
confirmed antiviral drug resistance. Genotypic resistance
testing is particularly important in guiding the choice of
rescue therapy for patients who have been exposed to
more than 1 nucleos(t)ide analogue as multidrug resis-
tance mutants have been reported in patients who have
received sequential monotherapies.9-11
A variety of assays have been used for the detection of
HBV antiviral drug–resistant mutations (Table 2). Di-
rect (population) sequencing is the least sensitive
method for detecting minor populations of drug resis-
tance mutants. This method requires that the mutant
population composes approximately 20% of the total
HBV quasispecies pool for detection. However, direct
sequencing allows all mutations to be identified, and
this is important when we are evaluating resistance to
new therapies for which the full spectrum of resistant
mutations has not been determined and when we are
evaluating drug resistance in patients who have re-
ceived multiple nucleos(t)ide analogues. Other assays
such as restriction fragment length polymorphism and
reverse hybridization (line probe) assays can detect vi-
ral mutants that constitute as little as 5% of the total
viral population.12,13 Because these assays are more
sensitive, they enable earlier identification of patients
with genotypic resistance14,15 and may be particularly
useful in the management of liver transplantation pa-
tients. A major disadvantage of these assays is that they
TABLE 1. Nomenclature for Antiviral Resistance
Term Definition
Virologic breakthrough Increase in serum HBV DNA by 1 log10 above nadir
while patient is on treatment after achieving initial
response
Biochemical breakthrough Increase in serum alanine aminotransferase while patient
is on treatment after achieving initial response
Genotypic resistance Detection of amino acid substitutions in the reverse
transcriptase region of the HBV polymerase gene that has
been shown to decrease susceptibility to treatment
Phenotypic resistance In vitro confirmation that the mutation decreases
susceptibility to treatment
Abbreviation: HBV, hepatitis B virus.
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can detect only known mutations, and existing assays
may not detect all mutations that have been shown to be
associated with resistance to HBV antiviral drugs. Re-
cently, several ultrasensitive assays, such as single ge-
nome sequencing and mass spectrometry–based restric-
tion fragment mass polymorphism, which can detect
mutants that constitute 0.1% of the viral quasispecies,
have been used to detect antiviral drug–resistant HBV
mutations,16,17 but the utility of these ultrasensitive as-
says in predicting viral resistance and the need for mod-
ification of treatment has not been established.
MUTATIONS ASSOCIATED WITH RESISTANCE
TO NUCLEOS(T)IDE ANALOGUE THERAPIES
Mutations associated with antiviral resistance may be
classified as primary (being responsible for decreased
susceptibility to the drug) or compensatory (being re-
sponsible for restoring replication fitness of the mutant
virus). Signature mutations associated with resistance
to the approved HBV therapies have been characterized
(Table 3).4 As an increasing number of patients with
divergent HBV sequences are exposed to nucleos(t)ide
analogue therapies, additional mutations may be iden-
tified. However, caution must be exercised in attribut-
ing differences in HBV sequences as the cause of anti-
viral drug resistance, particularly when baseline
sequences are not available for comparison. Thus, the
significance of several mutations such as alanine-to-
threonine substitution at position 181 (rtA181T) and
resistance to adefovir, isoleucine-to-valine substitution
at position 233 (rtI233V) and primary nonresponse to
adefovir, and alanine-to-threonine substitution at po-
sition 194 (rtA194T) and resistance to tenofovir re-
mains controversial.18-21
Among nucleoside-naı̈ve patients, antiviral drug re-
sistance has been reported in up to 70% of patients
after 4 years of lamivudine, 29% after 5 years of adefo-
TABLE 2. Assays Used To Detect Antiviral Drug–Resistant Hepatitis B Virus Mutations
Assay Advantages Disadvantages
Direct sequencing Detects all mutations Least sensitive at detecting minor
populations (20%)
Most useful with new
therapies




RFLP, line probe Sensitive (5%) Detects only known mutations





Ultrasensitive (0.1%) Cannot differentiate spontaneous
mutations from mutations
selected during treatment
Abbreviations: MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; RFLP, restriction fragment length
polymorphism.





L80, V173L, L180M Compensatory
Telbivudine M204I Resistance
L80, L180M Compensatory
Adefovir A181V or N236T Resistance
A181T Resistance





*Initial report of resistance not confirmed.
†In association with M204V/I.
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vir, 1% after 5 years of entecavir, and 9% to 22% after 2
years of telbivudine.22-25 Resistance rates are substan-
tially higher in patients with prior resistance to lamivu-
dine, with rates of up to 20% after 2 years of switching
to adefovir monotherapy and 51% after 5 years of
switching to entecavir.25,26
TREATMENT OF PATIENTS WITH ANTIVIRAL
DRUG–RESISTANT HBV
Optimal management of patients with antiviral drug–
resistant HBV requires knowledge of the past history
of HBV treatments and virologic response to those
treatments, patterns of mutations detected at the
time of virologic breakthrough, and in vitro cross-
resistance data. Rescue therapy should be initiated
early when virologic breakthrough is confirmed to be
due to drug resistance.27 If genotypic resistance test-
ing is not readily available, rescue therapy should be
initiated in patients who have virologic breakthrough
despite medication compliance. Options for rescue
therapy against antiviral drug–resistant HBV are
listed in Table 4.4,28
Lamivudine and telbivudine resistance
Lamivudine and telbivudine are L-nucleosides that se-
lect for mutations at the same site: methinone to valine
or isoleucine at position 204 (rtM204V/I) for lamivu-
dine and only rtM204I for telbivudine. In vitro studies
demonstrated that adefovir, tenofovir, and entecavir
have antiviral activity against rtM204V/I. The antiviral
activity of adefovir against rtM204V/I is comparable to
its activity against wild-type HBV, but its activity
against rtA181T appears to be lower.29,30 A pilot study
in patients with lamivudine-resistant HBV reported
that adefovir monotherapy resulted in similar rates of
viral suppression when compared with combination
therapy of lamivudine and adefovir.31 However, the
combination of lamivudine plus adefovir has been
shown to be more effective in preventing adefovir resis-
tance than adefovir monotherapy.32,33
In a study of 467 pretransplant and posttransplant
patients who received additional adefovir for lamivu-
dine-resistant HBV, serum HBV DNA became undetect-
able in 59% of wait-listed patients and 40% of post-
transplant patients after 48 weeks of treatment.34
Nephrotoxicity, defined as a confirmed increase in se-
rum creatinine by 0.5 mg/dL from baseline, was ob-
served in 6% of wait-listed patients, 47% of patients
who underwent liver transplantation during the course
of the study, and 21% of posttransplant patients. Many
patients were receiving concomitant nephrotoxic med-
ications, and some developed hepatorenal syndrome
during the course of the study; thus, it is difficult to
determine the role of adefovir in the worsening of renal
function in these patients. In this study, only 9 patients
had a confirmed decrease in serum phosphorus to 2
mg/dL. Serum creatinine should be closely monitored
in all liver transplant patients receiving adefovir (and
tenofovir), and dose adjustments should be made ac-
cording to renal function.
Tenofovir has also been shown to be effective in sup-
pressing lamivudine-resistant HBV in clinical stud-
ies.35,36 At the approved dose of 300 mg daily, tenofovir
has more potent antiviral activity than 10 mg of adefovir
and a similar safety profile.37-40
The activity of entecavir against lamivudine-resistant
HBV is significantly lower than its activity against wild-
type HBV, and the presence of an rtM204V/I mutation
decreases the genetic barrier to entecavir resistance.41
Clinical studies showed that despite the use of a higher
dose (1.0 versus 0.5 mg/day in patients without lami-
vudine resistance), a 48-week course of entecavir sup-
pressed serum HBV DNA to undetectable levels in a
smaller percentage of hepatitis B e antigen–positive
lamivudine-refractory patients (19% versus 67%), and
continued treatment for up to 5 years resulted in a
higher rate of entecavir resistance (50% versus 1% after
5 years of treatment) in comparison with nucleos(t)ide
naı̈ve patients.25,42
The best approach for patients with lamivudine resis-
tance is to continue lamivudine and add adefovir. In
patients with suboptimal viral suppression and those
with the rtA181T mutation, tenofovir may be substi-
tuted for adefovir. Tenofovir should replace adefovir
when it is approved for HBV treatment because it has
more potent antiviral activity. Entecavir is not an opti-
mal treatment for lamivudine-refractory patients be-
cause of the high risk of subsequent entecavir resis-
tance. This same approach can be applied to patients
with telbivudine resistance.
Adefovir resistance
In vitro studies have demonstrated that lamivudine,
telbivudine, and entecavir all have antiviral activity
TABLE 4. Treatment Options for Patients with Antiviral Resistance
Type of Resistance Rescue Therapy
Lamivudine or telbivudine resistance Add adefovir or tenofovir.
Switch to emtricitabine and tenofovir.
Adefovir resistance* Add lamivudine or switch to emtricitabine and tenofovir.
Add entecavir.
Entecavir resistance* Add adefovir or tenofovir.
Multidrug resistance ?
* Limited in vivo data.
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against adefovir-resistant mutations, but the activity of
lamivudine (and likely telbivudine) against the
rtA181V/T mutation is lower in comparison with wild-
type HBV.43
Clinical data regarding rescue therapy for patients
with adefovir-resistant HBV are limited. Case reports
have suggested that lamivudine is effective in suppress-
ing serum HBV DNA levels in patients with adefovir
resistance.44,45 However, the durability of response,
particularly in patients with previous lamivudine resis-
tance, is unknown. Furthermore, re-emergence of lami-
vudine-resistant mutations in this population has been
observed within a few months of the reintroduction of
lamivudine.11 Tenofovir has been reported to result in
decreases in serum HBV DNA levels in patients with
adefovir-resistant HBV, possibly because of the higher
dose used: 300 mg versus 10 mg for adefovir. However,
the efficacy of tenofovir monotherapy in this setting is
limited because of cross-resistance between tenofovir
and adefovir.46,47 Entecavir has been shown in case
reports to be effective in suppressing adefovir-resistant
HBV.26
The best approach to treating patients with adefovir
resistance is to add lamivudine, telbivudine, or ente-
cavir (Table 4). Entecavir may be a better option for
patients with previous lamivudine resistance and in
patients with the rtA181V/T mutation.
Entecavir resistance
Resistance to entecavir occurs through a 2-hit mecha-
nism.41 Initially, HBV with an rtM204V/I mutation is
selected because these mutants are less sensitive to
entecavir in comparison with wild-type HBV. Virologic
breakthrough occurs only after the emergence of addi-
tional entecavir resistance mutations at codons 184,
202, and 250. Entecavir resistance mutations are sen-
sitive to adefovir and tenofovir in vitro, but in vivo data
supporting their efficacy are based on isolated case
reports only.26,48,49
The only option for treating patients with entecavir
resistance is to add adefovir or tenofovir (Table 4).
HBIG resistance
Mutations in the hepatitis B surface protein have been
detected in patients who developed HBV reinfection af-
ter liver transplantation despite HBIG prophylaxis. The
most common mutation involves glycine-to-arginine
substitution at position 145 (sG145R).50 Lamivudine
has been shown to be effective in suppressing serum
HBV DNA levels in posttransplant patients who re-
ceived HBIG prophylaxis only and who developed recur-
rent hepatitis B.51,52 It is likely that other HBV nucleo-
s(t)ide analogues have similar efficacy.
Multidrug resistance
Sequential treatment with nucleos(t)ide analogue
monotherapy has resulted in the sequential selection of
mutations conferring resistance to both the initial and
subsequent rescue therapy.10,11 Combinations of mu-
tations to antiviral drugs and HBIG have also been
reported in liver transplant recipients who received an-
tiviral therapy and HBIG prophylaxis.9 The best ap-
proach to treating patients with multidrug resistance is
unclear. Careful characterization of the pattern of mu-
tations is needed to guide the choice of rescue therapy
in these patients.
CONCLUSIONS
Antiviral drug resistance is the most important cause of
HBV reinfection after liver transplantation; therefore,
every effort must be made to prevent its occurrence.
Initial therapy should use the most potent nucleos(t)ide
analogue with the highest genetic barrier to resistance,
and the importance of medication compliance should
be emphasized. Response should be closely monitored,
and modification of treatment should be considered in
patients who fail to achieve rapid virus suppression.
Combination therapy with another drug that is not
cross-resistant should be used if antiviral drugs with a
low genetic barrier to resistance such as lamivudine or
telbivudine or drugs with weak antiviral activity such as
adefovir are used in liver transplant patients. Whether
de novo combination therapy offers any advantage com-
pared to monotherapy with potent drugs that have a
high genetic barrier to resistance remains to be tested.
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